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MicroRNAs (miRNAs) are a class of non-coding RNA, which have recently been shown to have a wide variety of
regulatory functions in relation to gene expression. Since their identification nearly 20 years ago, miRNAs have been
found to play an important role in cancer, including in neurofibromatosis type 1 (NF1)-associated tumours. NF1 is
the most commonly inherited tumour predisposition syndrome and can lead to malignancy via the development
of malignant peripheral nerve sheath tumours (MPNSTs). Although the mechanisms by which benign
neurofibromas develop into MPNSTs still remain to be elucidated, it is becoming increasingly clear that miRNAs
play a key role in this process and have the potential to be used as both diagnostic and prognostic markers of
tumorigenesis.
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miRNAs constitute a category of small RNAs, ranging
between 19 and 25 nucleotides in length, which are gen-
erated from endogenous hairpin-shaped transcripts.
They function predominantly as post-transcriptional reg-
ulators of gene expression by hybridizing to the 30 un-
translated regions (30UTRs) of target mRNA molecules
[1,2], leading to translational repression or cleavage of
the target mRNA [3]. The first described miRNA, known
as lin-4, was discovered in Caenorhabditis elegans by
Lee et al. in 1993 [4]. This was later followed by the dis-
covery of let-7 [5], which was found to be highly con-
served across many different species [6], indicating the
widespread existence of miRNAs in eukaryotes. More
than 1,500 human miRNA sequences have been reported
in the human genome to date (miRBase; http://www.
mirbase.org/), of which 50% have been found to occur
within clusters, targeting either the same or different
genes within the same biological pathway [7]. It has be-
come apparent that miRNAs regulate the expression of
at least 30% of all protein-coding genes in mammalian
genomes [8], underlining their likely role in human gen-
etic disease. Novel techniques developed for the identifi-
cation of miRNAs have been instrumental in the rapid* Correspondence: upadhyaya@cardiff.ac.uk
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reproduction in any medium, provided the orprogress made by miRNA research. miRNAs play an im-
portant role in the development and progression of can-
cer. With an ever-increasing number of studies focusing
on the roles of miRNAs in cancer, whether operating as
oncogenes or tumour suppressor genes, our understand-
ing of the way in which miRNAs function is steadily im-
proving, and hence the number of potential therapeutic
applications for miRNAs should also increase.
In this review, the structure, function and biogenesis
of miRNA molecules are discussed in reference to the
recent developments that focus upon the role of miR-
NAs in relation to neurofibromatosis type 1.miRNA biogenesis, export and function
The process of miRNA biogenesis involves miRNA tran-
scription, the transport of the miRNAs to the cytoplasm
and subsequent maturation. miRNA biogenesis has been
reviewed in detail by Ladomery et al. [9] and will not be
specifically discussed here. However, the basic process
has been summarised in Figure 1.
The mechanism by which mature miRNAs regulate
gene expression depends upon the level of complemen-
tarity that exists between the miRNA and its target
mRNA [17]. Gene silencing can be effected either by
mRNA degradation or by inhibiting the mRNA from
being translated. It has been shown that if there is
complete complementarity between the miRNA andLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 The flowchart highlights the processes involved in
the following miRNA biogenesis: (1) The process begins
inside the nucleus, where RNA polymerase II or III initiates
the transcription of miRNA-coding genes to produce
‘pri-microRNA’s [10,11]. (2) A microprocessor complex comprising
both Drosha, an RNase III class enzyme, and Pasha, identifies and
cleaves pre-microRNAs generating pre-microRNAs [12-14]. (3)
Pre-microRNA molecules are transferred to the cytoplasm through
exportin-5-mediated transport, which uses GTP that is bound to the
Ran protein. The function of exportin-5 is dependent upon the
GTP-bound form of the Ran co-factor for specific binding to the
corresponding substrates. Therefore, this process comprises the
hydrolysis of Ran-GTP to Ran-GDP, via the Ran GTPase-activating
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the Argonaute protein family, can carry out strand selec-
tion and separation causing an RNA-induced silencing
complex (RISC) to bind to its mRNA target, leading to
mRNA degradation which in turn impacts upon transla-
tion [18]. If, however, the complementarity is imperfect,
as seen in most cases, translational repression ensues
[19]. Therefore, the main function of miRNAs appears
to be in the context of gene regulation via mRNA deg-
radation. Rarely, miRNAs can also bring about histone
modification and DNA methylation of gene promoterprotein in the cytoplasm [15,16]. (4) In the cytoplasm, Dicer acts to
cleave pre-miRNA molecules and, with the action of Argonaute 2
which is required for miRNA-induced silencing, forms an
RNA-induced silencing complex (RISC) leading to the creation of a
miRNA-induced silencing complex (miRISC). (5) Interaction between
the miRNA and its target mRNA in the miRISC can cause either
translational repression or miRNA degradation depending upon the
degree of complementarity.regions, thereby indirectly altering the expression of tar-
get genes [20,21].
Methodologies
miRNA expression profiles can be used both to
categorize different types of cancer and to identify
miRNA markers that can help in making prognostic pre-
dictions [22]. Initially, northern blotting was used to de-
tect pre-miRNAs and mature miRNAs and to provide
information about the regulation of the enzymes
involved in miRNA biogenesis [23]. Real-time polymer-
ase chain reaction (PCR) and microarray techniques
have also been tailored to detect the expression of pre-
miRNAs and mature miRNAs using either SYBR Green
dye or TaqMan probes (Sigma-Aldrich Corporation, St.
Louis, MO, USA) [24]. Further, Liu et al. in 2004 [25]
used oligonucleotide microchips to identify distinct
miRNA expression patterns in breast cancer and B cell
chronic lymphocytic leukaemia. Nevertheless, miRNA
microarray techniques are constantly being improved;
thus, Neely et al. in 2006 [26] developed modified oligo-
nucleotide arrays where probes for each miRNA were
designed and labelled with different fluorophores
whereas Lu et al. in 2005 [27] used a flow cytometry-
based method analysis to demonstrate expression of
miRNAs from a range of different samples. Both meth-
ods allowed the quantification of miRNA expression,
thereby making cancer diagnosis through miRNA ana-
lysis more specific and accurate. The advantage of using
miRNAs as markers instead of mRNAs lies in their abil-
ity to aid the classification of poorly differentiated can-
cers, as evidenced by the study by Rosenfeld et al. in
2008 [28], suggesting that miRNAs can be used to cor-
rectly identify the tumour tissue of origin.








miR-34a Down-regulated Tumour suppressor [37]
miR-214 Over-expressed Oncogene [37]
miR-10b Over-expressed Oncogene [37,38]
miR-29c Down-regulated Tumour suppressor [39]
miR204 Down-regulated Tumour suppressor [40]
miRNA-21 Over-expressed Oncogene [41]
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studied by looking not only at their single nucleotide
polymorphisms (SNPs) but also at their copy number
variation (CNV). Functional polymorphisms in the
30UTRs of miRNA genes have been reported to be asso-
ciated with cancer by virtue of their altering gene ex-
pression. SNPs may occur in miRNA biogenesis pathway
genes, primary miRNAs, pre-miRNAs or mature miRNA
sequences and have the potential to affect the efficiency
of miRNA binding to their target sites or alternatively
can create or disrupt miRNA binding sites [29]. In a re-
cent study, Gong et al. [30] identified 48 SNPs in human
miRNA seed regions and a large number of SNPs in
30UTRs with the potential to either disturb or create
miRNA target interactions. They confirmed the loss-of-
function and gain-of-function SNPs by luciferase assay.
Zhang et al. in 2006 [31] found that a large proportion
of loci containing miRNA genes exhibited somatic copy
number alterations and, amongst the three cancer types,
they identified 41 miRNAs with copy number changes.
These miRNA copy number changes also correlated with
the levels of miRNA expression in these cancers. High
frequency copy number changes were also noted in the
genes encoding Dicer (DICER1) and Argonaute 2
(EIF2C2), both of which are required for miRNA biogen-
esis. These findings are compatible with the view that
somatic miRNA copy number changes are common in
cancer and could potentially account for at least a pro-
portion of the miRNA deregulation found in many
tumour types. Using bioinformatic tools, Marcinkowska
et al. in 2011 [32] have demonstrated that miRNA loci
are under-represented in highly polymorphic and well-
validated CNV regions. Thus, CNV-miRNAs represent
functional variants of potential importance for genotype/
phenotype association studies.
miRNAs in neurofibromatosis type 1
Neurofibromatosis type 1 (NF1), a familial tumour pre-
disposition syndrome, is characterised by the growth of
benign and malignant tumours involving the peripheral
and central nervous system. NF1 results from inactivat-
ing germline mutations of the NF1 gene located at
17q11.2 [33]. Most NF1 patients develop multiple be-
nign cutaneous neurofibromas, with approximately 30%
to 50% of patients also developing larger plexiform
neurofibromas. About 10% of patients eventually de-
velop malignant peripheral nerve sheath tumours
(MPNSTs), which are aggressive tumours that pose sig-
nificant diagnostic and therapeutic challenges. Half of all
MPNSTs diagnosed occur in association with NF1, with
affected patients exhibiting a poor prognosis. With no
effective treatment available, radical surgery and chemo
and radiotherapy are required to reduce tumour recur-
rence and metastasis and prolong patient survival.The process of MPNST pathogenesis is poorly under-
stood owing to its complex histopathology and the
underlying molecular mechanisms. Biallelic NF1 gene in-
activation is essential for tumour development. However,
it is now known that additional molecular changes and
the tumour micro-environment are associated with the
progression of this type of tumour. There is currently no
defined molecular signature for MPNST development.
Constitutive activation of several critical cell signalling
cascades also occurs in MPNSTs. Multidisciplinary col-
laborative efforts are clearly essential to fully decipher
both the complex molecular basis of MPNST develop-
ment and to define potential therapeutic targets.
A general characteristic of cancer cells is uncontrolled
growth and, in many cases, miRNAs can either promote
or suppress this growth. Previous investigations have
shown that miRNAs have key functions in the develop-
ment of cancer, in relation to a range of different cellular
processes including cell differentiation, developmental
control, neural development, cell proliferation, apoptosis
[34,35] and organ development [3]. Thus, the role of a
given miRNA in cancer pathogenesis can be categorised
as being either of oncogene or tumour suppressor gene
nature. Moreover, it is thought that >50% of miRNA-
coding genes are located in cancer-associated genomic
regions or in fragile sites [36]. It is now known that miR-
NAs are associated with a range of different cancers, in-
cluding chronic leukaemias, acute leukaemias and
myelodysplastic syndromes, lymphomas, multiple mye-
loma, hepatocellular carcinoma, breast, lung and colon
cancer, amongst others.
Several research groups have studied the role of
miRNA in NF1-associated malignancy. Here we focus
on miRNAs miR-29c, miR-34a, miR-214, miR-10b,
miR204 and miR-21 which have previously been directly
implicated in NF1 tumorigenesis (summarized in
Table 1).
miR-34a
One of the earliest studies of miRNAs in NF1 was car-
ried out by Subramanian et al. [37]. Their genome-wide
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of malignancy from neurofibroma to MPNST correlates
with the loss of expression of a number of genes rather
than an increase in expression. This subsequently led
to miRNA expression profiling which demonstrated the
down-regulation of miR-34a in most MPNSTs as com-
pared to neurofibromas. This loss of miR-34a could
contribute to the development of malignancy. miR-34 is
known to be a direct target of p53 in a variety of neo-
plasms including colorectal carcinoma and neuroblast-
oma in which lower levels of this miRNA are
associated with the suppression of apoptosis. Forced ex-
pression of miR-34a in MPNST cell lines that are defi-
cient in miR-34a leads to increased apoptosis whereas
the forced expression of p53 in the same cell line
results in a similar effect, indicating that the expression
of p53 results in apoptosis through a mechanism in-
volving miR-34a. The study of Subramanian et al. in
2010 also revealed an increase in the expression levels
of a further nine miRNAs, following induced expression
of p53 in MPNSTs. Interestingly, six of these (including
miR-638, miR-373, miR-492, miR-126, miR-140 and
miR-491), have been shown to be involved in promot-
ing tumorigenic processes such as invasion, prolifera-
tion and metastasis.
Using a systems biology approach, Lee et al. [42] iden-
tified a regulatory network which involved the E2F fam-
ily: E2F7/E2F8 in several cell cycle-related gene
modules. miR-34a over-expression was found to lead to
increased activity of E2F7/E2F8 transcription factors
and cell cycle genes. These transcription factors are dis-
proportionately associated with DNA damage repair, cell
growth and development [42,43], and the altered ex-
pression levels of this family of transcription factors has
been noted in cancerous cells [44], indicating that miR-
34a could be a target for therapeutic intervention. As
E2F transcription factors are involved in transcriptional
regulation as well as in DNA repair and cell prolifera-
tion, it is possible that an alteration in the expression of
activators and suppressors of E2F7 and E2F8 transcrip-
tion may play a role in the development of MPNSTs.
However, recent data by Presneau et al. [39] failed to
confirm the work by Subramanian et al. [37] regarding
miR-34a. This was deemed to be due either to differ-
ences in the methodologies used or to the use of differ-
ent groups of patients based on differences in NF1
diagnostic criteria. Recent reports indicate that miR-34a
has also been shown to act as a tumour suppressor
through its dysregulation in a number of other carcin-
omas including glioblastoma multiforme tumours [45],
breast cancer [46], head and neck squamous cell carcin-
oma [47] and osteosarcoma [48], suggesting that it
could represent a significant gene target in cancer
therapeutics.miR-214
Subramanian et al. [37] identified miR-214 as having the
highest expression level of all miRNAs screened in their
study of NF1-MPNSTs. miR-214 had previously been
shown to be expressed at an increased level in the blood
of breast and ovarian cancer patients, indicating that it
could be used as an indicator of malignancy [49,50].
Yang et al. [50] proposed that miR-214 induces cell sur-
vival and cisplatin resistance through targeting the
30UTR of the PTEN gene, which leads to down-
regulation of the PTEN protein and the activation of the
Akt pathway, thereby promoting cell survival. More re-
cently, Peng et al. [51] found that miR-214 can inhibit
cancer cell proliferation and migration by targeting
GALNT7. This is supported by data from Shih et al.
[52], who showed that miR-214 down-regulation can
contribute to tumour angiogenesis and is associated with
increased tumour recurrence and a poor prognosis. In
their study, Subramanian et al. [37] also identified a
metastasis-promoting factor, TWIST1, as promoting ex-
pression of miR-214. TWIST1 had previously been noted
to increase metastasis in a number of different carcin-
omas, but its exact role in NF1 tumorigenesis has not
yet been elucidated. Taken together with the above data,
it is suggested that TWIST1 may regulate miR-214 ex-
pression thereby contributing to tumorigenesis [53].
miR-10b
By inhibiting the expression of miR-10b in NF1-MPNSTs,
Subramanian et al. [37] demonstrated decreased cell
proliferation and migration, indicating an important
function for miR-10b in the transformation of benign
NF1-associated neurofibromas to MPNSTs. These workers
also showed that the expression of miR-10b is consid-
erably higher in NF1-MPNST cell lines, NF1-MPNST
tumour tissues and primary Schwann cells by com-
parison with benign neurofibromas. This suggests
that miR-10b could act as a biomarker to differentiate
between NF1-MPNSTs and neurofibromas. miR-10b
belongs to the miR-10 cluster of miRNAs and is highly
conserved between different species. Its location within
the Hox gene clusters suggests that it could share the
same mechanisms of regulation as the Hox genes [54].
Supporting this notion that over-expressed miRNAs of
the miR-10 family may play a role in cancer, miR-10b
has also been found to be overexpressed in B cell
chronic lymphocytic leukaemia [36] as well as in acute
myeloid leukaemias associated with mutations in the
NPM1 gene [55].
miR-10b expression has also been shown as enhanced
by increased expression of TWIST1 in MPNST cells [56].
Chai et al. [38] have suggested that it is the increased ex-
pression of TWIST1 that may cause increased expression
of miR-10b in the MPNSTs of NF1 patients. In their
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patients with those from sporadic tumours, Chai et al.
[38] identified miR-10b, miR-155 and miR-335 as being
over-expressed and Let-7a and Let-7b as being under-
expressed in the NF1-MPNST cell lines. Further investi-
gation showed that miR-10b reduced cell migration,
invasion and proliferation. While inhibiting miR-155 did
not correct the abnormal growth behaviour of NF1
MPNST cells, inhibiting miR-335 or enhancing let-7a
expression partially corrected some abnormal growth
properties of these tumour cells. These findings suggest
that changes in miR-155 may represent a consequence
of NF1 MPNST tumour formation, while changes in
miR-335 and let-7 expression may contribute to progres-
sion of NF1 MPNSTs. These speculations are supported
by the observation that RAS and tenascin C are deregu-
lated in NF1 MPNSTs. Subsequently, these authors went
on to demonstrate that miR-10b targets the NF1 mRNA
30UTR, thereby repressing the expression of neurofibro-
min protein. Therefore, it is suggested that miR-10b
could specifically target neurofibromin to control NF1
tumorigenesis and progression. Irrespective of whether
or neurofibromin is functional, as long as there is
expression of the NF1 mRNA, it is possible for the
miR-10b to target its 30UTR to suppress expression of
neurofibromin protein. Chai et al. [38] also suggested
that miR-10b could target other genes, and co-operate
with other miRNAs such as miR-335 and let-7, to promote
NF1 tumorigenesis and progression.
miR-29c
Presneau et al. [39] aimed to identify a molecular target
to help discriminate between neurofibromas and
MPNSTs. In their study of ten matched pairs of samples
of MPNSTs and neurofibromas from NF1 patients,
Presneau et al. [39] showed miR-210 to have been
upregulated, and a series of miRNAs to have been
down-regulated (miR-30e, miR-30c, miR-340, miR-139-5p,
miR-29c and Let-7g) in MPNSTs. Of these miR-29c was
the most down-regulated; the gene targets of miR-29c
include COL1A1, COL21A1, COL5A2 and TDG, all of
which were down-regulated in MPNSTs. This was con-
firmed using synthetic oligonucleotide mimics. Further
assays showed increased migration and invasion of
MPNST cells following treatment with a miR-29c
mimic. Presneau et al. [39] postulated that the de-
creased expression levels of miR-29c are mediated by
the activation of a hepatocyte growth factor receptor,
cMET, which has been shown to be activated in
MPNSTs. This hypothesis is supported by the findings
of Kwiecinski et al. [57] who demonstrated that hepato-
cyte growth factor receptor can inhibit collagen synthe-
sis by activating miR-29a and miR-29b. Together, these
data suggest that miR-29c is regulated by the action ofcMET which, when activated, can stimulate miR-29 to
control cell migration and invasion. Thus, miR-29c can
act as a tumour suppressor and could potentially be
used as a means to distinguish malignant from benign
tumours. This suggestion has been borne out by find-
ings in colorectal cancer, where analysis of mRNA ex-
pression profiles has indicated that miR-29c can predict
the recurrence of colorectal cancer [58], and in hepatitis
B virus-related hepatocellular carcinoma, where miR29c
inhibits cell proliferation and promotes apoptosis [59].
miR-204
Recently, Gong et al. [40] reported that miR-204 contri-
butes to the growth of MPNSTs, particularly in NF1.
They postulated that this miRNA plays an important
role in the carcinogenic process as it is found in cancer-
associated regions of the genome and has previously
been shown to be subject to high-frequency loss of het-
erozygosity in tumours [60]. miR-204 has also been
found to act as a tumour suppressor gene in various
other tumours including breast, kidney and prostate
cancers [61]. This study demonstrated that the expres-
sion of miR-204 is down-regulated in tissue, which is
derived from both NF1- and non-NF1-related tumours.
By inducing the expression of miR-204 in MPNSTs of
both NF1 and non-NF1 origin, the abnormal cellular
characteristics were reversed and cell proliferation was
reduced. Specifically in an NF1-related tumour cell line,
induced expression of miR-204 resulted in decreased
progression of malignancy and tumour development.
Further bioinformatic analysis revealed that miR-204 tar-
gets HMGA2, a gene that regulates RAS signalling, sug-
gesting that miR-204 may also contribute indirectly to
the development of malignancy. It was also found that
HMGA2 expression is inhibited by miR-204, revealing
an alternative pathway for tumour progression. It is still
not clear whether miR-204 alone is sufficient to promote
carcinogenesis in MPNSTs, as earlier studies have indi-
cated that p53 inactivation and subsequent loss of ex-
pression of miR-34a may contribute to MPNST
development [37]. Although these results have only been
confirmed in vitro, miR-204 could potentially act as a
biomarker for cancer diagnosis as well as an effective
target for the development of therapeutic treatment.
miR-21
In a recent study, Itani et al. [41] analysed a panel of 12
MPNSTs, 11 neurofibromas, five normal nerves and
three MPNST cell lines by mRNA expression profiling.
The expression of miR-21 was significantly higher in
MPNSTs than in the neurofibromas or MPNST cell
lines. Transfection of miR-21 inhibitor significantly
increased caspase activity (p < 0.001) and suppressed cell
growth (p < 0.05) while upregulating the level of PDCD4
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likely to play an important role in MPNST progression
through its target PDCD4.
NF1 microdeletions
It has been estimated that 5% of NF1 patients possess a
germline 1.4-Mb microdeletion [62]. This results from
the unequal recombination between two homologous
NF1 low copy-number repeats [63]. NF1-microdeleted
patients have an increased risk of developing MPNSTs
[64]. They also appear to exhibit a more severe clinical
phenotype in comparison to individuals with intragenic
NF1 mutations [65]. Analysis of the NF1 microdeleted
region reveals that it contains a minimum of 16 protein
coding genes, four pseudogenes and two microRNAs
[66]. A recent study by Pasmant et al. [67] looked at the
two miRNAs located within the 1.4-Mb microdeleted re-
gion in a set of MPNSTs and benign neurofibromas of
NF1 microdeleted patients. They found that the two
miRNA genes (MIR3652 and MIR193A at 17q11.2 en-
coding miR-365-2 and miR-193a, respectively) displayed
no differences in the expression between the tumour
types, despite miR-193a having been previously catego-
rized as a tumour suppressor in oral squamous cell
carcinoma [68] and despite miR-365-2 having been
identified as having an anti-proliferative role in colon
cancer [69]. Further study will be required to assess
the possible role of these two miRNAs in NF1
tumorigenesis.
NF1-phaeochromocytomas
Tömböl et al. [70] analysed the expression pattern of
miRNAs in patients with NF1-associated pheochromo-
cytomas by real-time quantitative reverse-transcription
PCR. The results of their study revealed 16 differentially
expressed miRNAs; their pathway analysis suggested that
Notch- and G-protein-coupled receptor signalling may
be involved in tumour recurrence. These authors also
demonstrated the successful use of formalin-fixed paraf-
fin-embedded samples for the analysis of miRNAs in
phaeochromocytomas.
Epigenetic regulation of microRNAs in cancer
DNA methylation in the 50 regulatory regions of genes is
a major epigenetic mechanism. The role of aberrant
DNA hypermethylation in the regulation of miRNA ex-
pression in human cancer has also been explored [71].
This study identified 122 miRNAs which were reported
to be epigenetically regulated in 23 cancer types. Human
oncomirs (miRNAs) with a role in cancer are designated
as oncogenic miRNAs or oncomirs. High methylation
levels compared to the protein-coding genes and at least
half of the epigenetically regulated miRNAs were
involved with different cancer types.Both DNA methylation and mRNA regulation can
suppress gene expression and their corresponding gene
product. Su et al. [72] demonstrated that miRNAs tend
to target genes with a low level of DNA methylation
level in their promoter regions. They also found that
miRNA target sites were significantly enriched in genes
located in differentially methylated regions or partially
methylated domains and that cancer genes tend to be
characterized by a low level of methylation and more
miRNA target sites.
miRNAs as prognostic and diagnostic biomarkers
Dysregulation of miRNAs is fundamental to the patho-
genesis of many cancers. miRNAs that regulate the ex-
pression of tumour suppressor genes and oncogenes are
candidates for use in targeted therapies [73]. An
improved understanding of the underlying molecular
mechanisms is still required for many cancers so as to
make possible the development of effective targeted
therapies. Krutzfeldt et al. [74] created chemically modi-
fied antagomirs, molecules which are complementary to
miRNAs and which provide a useful way of silencing
specific miRNAs in vivo. Just as one miRNA may regu-
late multiple targets, one target may also be regulated by
a number of different miRNAs. Hence, specificity is an
important factor to consider in designing a therapeutic
approach.
miRNAs are increasingly being identified as useful
diagnostic and prognostic markers. One example of this
is in hepatocellular carcinoma (HCC) in which it has
been shown that low levels of miR-26 can be indicative
of a poor prognosis [75]. These patients have also been
shown to benefit from a specific type of interferon-α
therapy, showing that miR-26 can be used to identify
HCC patients who would be more likely to respond
well to this type of treatment. miRNAs can also be
shown to overcome drug resistance when targeted, in
chemo-resistance [76] and resistance to anti-oestrogenic
therapies [77,78], demonstrating the range of different
treatment methods to which miRNAs can contribute.
miRNA delivery may be used to counteract carcinoge-
nesis. miRNAs are reliable biomarkers for testing the
efficiency of chemoprevention and may be used to
counteract carcinogenesis [79].
As well as individual miRNAs being able to act as bio-
markers and therapeutic targets, Han et al. [80], have
shown that the three genes involved in miRNA biogen-
esis, namely DICER1, DROSHA and XPO5 (exportin 5),
have also been shown to have therapeutic potential, at
least in the case of bladder urothelial carcinoma. These
genes are vital for miRNA development, and their silen-
cing results in the inhibition of cell proliferation and
apoptosis. Han et al. [80] showed that all three genes
were up-regulated and had higher expression in high-
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differential expression patterns indicate that DICER1,
DROSHA and XPO5 could play active roles in
carcinogenesis.
The use of miRNAs as useful biomarkers of tumori-
genesis is supported by the finding that they are secreted
into bodily fluids [81] and, hence, are circulating around
the body so that they can be easily and accurately
observed by means of microarray and quantitative PCR
methods, allowing their detection to be both sensitive
and specific [82]. There are already clinical diagnostic
tests available that use miRNAs as biomarkers, such as
the ProOnc TumorSource Dx, a proprietary test offered
by Prometheus Labs (San Diego, CA, USA) (http://www.
prometheuslabs.com), that determines the expression
levels of 48 different miRNA biomarkers in a tissue sam-
ple, from which the results are used to determine the tis-
sue of origin of metastatic cancer.
Conclusions
The discovery of miRNAs nearly 20 years ago intro-
duced us to a new regulatory mechanism enabling a
better understanding of the molecular pathogenesis of
cancers. Dysregulation of miRNAs is fundamental to
the pathogenesis of many cancers. miRNAs have the
potential to target as many as several hundred genes
simultaneously making them attractive prognostic
biomarkers and therapeutic targets in cancer. miR-
NAs are not only involved in tumour progression, but
also play a role in cancer invasion, metastasis, epigen-
etic alterations, chemo-resistance and radio-resist-
ance. Although research on the role of miRNAs in NF1
tumorigenesis is still in its infancy, the experimental data
obtained so far indicate that a number of miRNAs may
be involved in NF1 tumorigenesis, including miR-29c,
miR-34a, miR-214, miR-10b, miR-204 and miR-21.
However, we lack an understanding of how different
miRNAs identified in NF1 tumours might interact with
neurofibromin and other tumour-associated proteins
and whether these miRNAs can be linked to specific
cancer signalling pathways. miRNAs involved in regulat-
ing the expression of oncogenes and tumour suppressor
genes are candidates for targeted therapy for NF1
tumours. Therefore, it is hoped that the study of these
small RNAs will eventually make a significant difference
in treating NF1, at least to delay, if not entirely elimin-
ate, the onset of tumorigenesis. The identification not
only of differentially expressed microRNAs in tumours
but also their target genes is providing new avenues for
therapeutic approaches. As with any new therapeutic
approach, there are of course many obstacles to be over-
come before miRNAs can be used in clinical practise.
However, it appears to present a very promising thera-
peutic avenue.Competing interests
The authors declare that they have no competing interests.Authors’ contributions
AS contributed to the compilation of the first draft, DNC and MU improved
the manuscript. All authors read and approved the final manuscript.
Received: 24 August 2012 Accepted: 26 September 2012
Published: 17 November 2012References
1. Ambros V: The functions of animal microRNAs. Nature 2001, 431:350–355.
2. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism and function.
Cell 2004, 116:281–297.
3. Lai EC: MicroRNAs are complementary to 30UTR sequence motifs that
mediate negative post-transcriptional regulation. Nat Genet 2002,
30:363–364.
4. Lee RC, Feinbaum RL, Ambros V: The C. elegans heterochronic gene lin-4
encodes small RNAs with antisense complementarity to lin-14. Cell 1993,
75:843–854.
5. Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, Rougvie AE,
Horvitz HR, Ruvkun G: The 21-nucleotide let-7 RNA regulates
developmental timing in Caenorhabtidis elegans. Nature 2000,
403:901–906.
6. Pasquinelli AE, Reinhart BJ, Slack FJ, Martindale MQ, Kuroda MI, Maller B,
Hayward DC, Ball EE, Degnan B, Muller P, Spring J, Srinivasan A, Fishman M,
Finnerty J, Corbo J, Levine M, Leahy P, Davidson E, Ruvkun G: Conservation
of the sequence and temporal expression of Let-7 heterochronic
regulatory RNA. Nature 2000, 408:86–89.
7. Yu J, Wang F, Yang GH, Wang FL, Ma YN, Du ZW, Zhang JW: Human
microRNA clusters: genomic organization and expression profile in
leukemia cell lines. Biochem Biophys Res Commun 2006, 13:59–68.
8. Sayed D, Abdellatif M: MicroRNAs in development and disease. Physiol Rev
2011, 91:827–887.
9. Ladomery MR, Maddocks DG, Wilson ID: MicroRNAs: their discovery,
biogenesis, function and potential use as biomarkers in non-invasive
prenatal diagnostics. Int J Mol Epidemiol Genet 2011, 2:253–260.
10. Lee Y, Jeon K, Lee JT, Kim S, Kim VN: MicroRNA maturation: stepwise
processing and subcellular localisation. EMBO J 2002, 23:4051–4060.
11. Zeng Y, Yi R, Cullen BR: Recognition and cleavage of primary microRNA
precursors by the nuclear processing enzyme Drosha. EMBO J 2005,
24:138–148.
12. Denli AM, Tops BBJ, Plasterk RHA, Ketting RF, Hannon GJ: Processing of
primary microRNAs by the microprocessor complex. Nature 2004,
432:231–235.
13. Gregory RI, Yan KP, Amuthan G, Chendrimada T, Doratotaj B, Cooch N,
Shiekhatter R: The microprocessor complex mediates the genesis of
microRNAs. Nature 2004, 432:235–240.
14. Landthaler M, Yalcin A, Tuschl T: The human DiGeorge syndrome critical
region gene 8 and its D. melanogaster homolog are required for miRNA
biogenesis. Curr Biol 2004, 14:2162–2167.
15. Yi R, Qin Y, Macara IG, Cullen BR: Exportin-5 mediates the nuclear export
of pre-microRNAs and short hairpin RNAs. Genes Dev 2003, 17:3011–3016.
16. Lund E, Guttinger S, Calado A, Dahlberg JE, Kutay U: Nuclear export of
microRNA precursors. Science 2004, 303:95–98.
17. Hwang HW, Mendell JT: MicroRNAs in cell proliferation, cell death and
tumourigenesis. Br J Cancer 2006, 94:776–780.
18. Matranga C, Tomari Y, Shin C, Bartel DP, Zamore PD: Passenger-strand
cleavage facilitates assembly of siRNA into Ago2-containing RNAi
enzyme complexes. Cell 2005, 123:607–620.
19. Winter J, Jung S, Keller S, Gregory RI, Diederichs S: Many roads to maturity:
microRNA biogenesis pathways and their regulation. Nat Cell Biol 2009,
11:228–234.
20. Tan G, Shi Y, Wu ZH: MicroRNA-22 promotes cell survival upon UV
radiation by repressing PTEN. Biochem Biophys Res Commun 2012, 2012
(417):546–551.
21. Hawkins PG, Morris KV: RNA and transcriptional modification of gene
expression. Cell Cycle 2008, 7:602–607.
22. Esquela-Kerscher A, Slack FJ: Oncomirs-microRNAs with a role in cancer.
Nat Rev Cancer 2006, 6:259–269.
Sedani et al. Human Genomics 2012, 6:23 Page 8 of 9
http://www.humgenomics.com/content/6/1/2323. Hammond SM: MicroRNA detection comes of age. Nat Methods 2006,
3:12–13.
24. Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, Barbisin M, Xu
NL, Mahuvakar VR, Andersen MR, Lao KQ, Livak KJ, Guegler KJ: Real-time
quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 2005,
33:e179.
25. Liu CG, Calin GA, Meloon B, Gamliel N, Sevignani C, Ferracin M, Dumitru CD,
Shimizu M, Zupo S, Dono M, Alder H, Bullrich F, Negrini M, Croce CM: An
oligonucleotide microchip for genome-wide microRNA profiling in
human and mouse tissues. Proc Nat Acad Sci USA 2004, 101:9740–9744.
26. Neely LA, Patel S, Garver J, Gallo M, Hackett M, McLaughlin S, Nadel M,
Harris J, Gullans S, Rooke J: A single-molecule method for the quantitation
of microRNA gene expression. Nat Methods 2006, 3:41–46.
27. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero
A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub
TR: MicroRNA expression profiles classify human cancers. Nature 2005,
435:834–838.
28. Rosenfeld N, Aharonov R, Meiri E, Rosenwald S, Spector Y, Zepeniuk M,
Benjamin H, Shabes N, Tabak S, Levy A, Lebanony D, Goren Y, Silberschein
E, Targan N, Ben-Ari A, Gilad S, Sion-Vardy N, Tobar A, Feinmesser M,
Kharenko O, Nativ O, Nass D, Perelman M, Yosepovich A, Shalmon B, Polak-
Charcon S, Fridman E, Avniel A, Bentwich I, et al: MicroRNAs accurately
identify cancer tissue origin. Nat Biotechnol 2008, 26:462–469.
29. Slaby O, Bienertova-Vasku J, Svoboda M, Vyzula R: Genetic polymorphisms
and microRNAs: new direction in molecular epidemiology of solid
cancer. J Cell Mol Med 2012, 16:8–21.
30. Gong J, Tong Y, Zhang HM, Wang K, Hu T, Shan G, Sun J, Guo AY: Genome-
wide identification of SNPs in microRNA genes and the SNP effects on
microRNA target binding and biogenesis. Hum Mutat 2012, 33:254–263.
31. Zhang L, Huang J, Yang N, Greshock J, Megraw MS, Giannakakis A, Liang S,
Naylor TL, Barchetti A, Ward MR, Yao G, Medina A, O'brien-Jenkins A,
Katsaros D, Hatzigeorgiou A, Gimotty PA, Weber BL, Coukos G: microRNAs
exhibit high frequency genomic alterations in human cancer. Proc Natl
Acad Sci USA 2006, 103:9136–9141.
32. Marcinkowska M, Szymanski M, Krzyzosiak WJ, Kozlowski P: Copy number
variation of microRNA genes in the human genome. BMC Genomics 2011,
12:183.
33. Upadhyaya M: Genetic basis of tumorigenesis in NF1 malignant
peripheral nerve sheath tumors. Front Biosci 2011, 16:937–951.
34. Cheng AM, Byrom MW, Shelton J, Ford LP: Antisense inhibition of human
miRNAs and indications for involvement of miRNA in cell growth and
apoptosis. Nucleic Acids Res 2005, 33:1290–1297.
35. Cimmino A, Calin GA, Fabri M, Iorio MV, Ferracin M, Shimizu M, Wojcik SE,
Aqelin RI, Zupo S, Dono M, Rassenti L, Alder H, Volinia S, Liu CG, Kipps TJ,
Negrini M, Croce CM: miR-15 and miR-16 induce apoptosis by targeting
BCL2. Proc Natl Acad Sci USA 2005, 102:13944–13949.
36. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu
M, Rattan S, Bullrich F, Negrini M, Croce CM: Human microRNA genes are
frequently located at fragile sites and genomic regions involved in
cancers. Proc Natl Acad Sci USA 2004, 101:2999–3004.
37. Subramanian S, Thayanithy V, West RB, Lee CH, Beck AH, Zhu S, Downs-Kelly
E, Montgomery K, Goldblum JR, Hogendoorn PC, Corless CL, Oliveira AM,
Dry SM, Nielsen TO, Rubin BP, Fletcher JA, Fletcher CD, van de Rijn M:
Genome-wide transcriptome analyses reveal p53 inactivation mediated
loss of miR-34a expression in malignant peripheral nerve sheath
tumours. J Pathol 2010, 220:58–70.
38. Chai G, Liu N, Ma J, Li H, Oblinger JL, Prahalad AK, Gong M, Chang LS,
Wallace M, Muir D, Guha A, Phipps RJ, Hock JM, Yu X: MicroRNA-10b
regulates tumourigenesis in neurofibromatosis type 1. Cancer Sci 2010,
101:1997–2004.
39. Presneau N, Eskandarpour MS, Henderson S, Halai D, Tirabosco R, Flanagan
AM: Micro-RNA profiling of peripheral nerve sheath tumours identifies
miR-29c as a tumour suppressor gene involved in tumour progression.
Br J Cancer 2012, doi:10.1038/bjc.2012.518.
40. Gong M, Ma J, Li M, Zhou M, Hock JM, Yu X: MicroRNA-204 critically
regulates carcinogenesis in malignant peripheral nerve sheath tumors.
Neuro Oncol 2012, 14:1007–1017.
41. Itani S, Kunisada T, Morimoto Y, Yoshida A, Sasaki T, Ito S, Ouchida M,
Sugihara S, Shimizu K, Ozaki T: MicroRNA-21 correlates with tumorigenesis
in malignant peripheral nerve sheath tumor (MPNST) via programmed
cell death protein 4 (PDCD4). J Cancer Res Clin Oncol 2012, 138:1501–1509.42. Lee Ming J, Choji H, Galas DJ, Wang K: The systems biology of
neurofibromatosis type 1 - critical roles for microRNA. Exp Neurol 2012,
235:464–464.
43. Lammens T, Li J, Leone G, De Veylder L: Atypical E2Fs: new players in the
E2F transcription factor family. Trends Cell Biol 2009, 19:111–118.
44. Reimer D, Sadr S, Wiedemair A, Stadlmann S, Concin N, Hofstetter G, Müller-
Holzner E, Marth C, Zeimet AG: Clinical relevance of E2F family members
in ovarian cancer - an evaluation in a training set of 77 patients.
Clin Cancer Res 2007, 13:144–151.
45. Yin D, Ogawa S, Kawamata N, Leiter A, Ham M, Li D, Doan NB, Said JW,
Black KL, Koeffler PH: miR-34a functions as a tumor suppressor
modulating EGFR in glioblastoma multiforme. Oncogene 2012,
10:1038.
46. Li L, Yuan L, Luo J, Gao J, Guo J, Xie X: MiR-34a inhibits proliferation and
migration of breast cancer hrough down-regulation of Bcl-2 and SIRT1.
Clin Exp Med 2012, doi:10.1007/s10238-012-0186-5.
47. Kumar B, Yadav A, Lang J, Teknos TN, Kumar P: Dysregulation of
microRNA-34a expression in head and neck squamous cell carcinoma
promotes tumor growth and tumor angiogenesis. PLoS One 2012,
7:e37601.
48. Yan K, Gao J, Yang T, Ma Q, Qiu X, Fan Q, Ma B: MicroRNA-34a inhibits the
proliferation and metastasis of osteosarcoma cells both in vitro and
in vivo. PLoS One 2012, 7:e33778.
49. Schwarzenbach H, Milde-Langosch K, Steinbach B, Müller V, Pantel K:
Diagnostic potential of PTEN-targeting miR-214 in the blood of breast
cancer patients. Breast Cancer Res Treat 2012, 134:933–941.
50. Yang H, Kong W, He L, Zhao JJ, O'Donnell JD, Wang J, Wenham RM,
Coppola D, Kruk PA, Nicosia SV, Cheng JQ: MicroRNA expression profiling
in human ovarian cancer: miR-214 induces cell survival and cisplatin
resistance by targeting PTEN. Cancer Res 2008, 68:425–433.
51. Peng RQ, Wan HY, Li HF, Liu M, Li X, Tang H: MicroRNA-214 suppresses
growth and invasiveness of cervical cancer cells by targeting UDP-N-
acetyl-α-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase
7. J Biol Chem 2012, 287:14301–14309.
52. Shih TC, Tien YJ, Wen CJ, Yeh TS, Yu MC, Huang CH, Lee YS, Yen TC, Hsieh
SY: MicroRNA-214 downregulation contributes to tumor angiogenesis via
inducing secretion of hepatoma-derived growth factor in human
hepatoma. J Hepatol 2012, 57:584–591.
53. Lee YB, Bantounas I, Lee DY, Phylactou L, Caldwell MA, Uney JB: Twist-1
regulates the miR-199a/214 cluster during development. Nucleic Acids Res
2009, 1:123–128.
54. Tanzer A, Amemiya CT, Kim CB, Stadler PF: Evolution of microRNAs located
within Hox gene clusters. J Exp Zool B Mol Dev Evol 2005, 304:75–85.
55. Garzon R, Garofalo M, Martelli MP, Briesewitz R, Wang L, Fernandez-
Cymering C, Volinia S, Liu CG, Schnittger S, Haferlach T, Liso A, Diverio D,
Mancini M, Meloni G, Foa R, Martelli MF, Mecucci C, Croce CM, Falini B:
Distinctive microRNA signature of acute myeloid leukemia bearing
cytoplasmic mutated nucleophosmin. Proc Natl Acad Sci USA 2008,
105:3945–3950.
56. Ma L, Teruya-Feldstein J, Weinberg RA: Tumour invasion and
metastasis initiated by microRNA-10b in breast cancer. Nature 2007,
449:682–688.
57. Kwiecinski M, Noetel A, Elfimova N, Trebicka J, Schievenbusch S, Strack I,
Molnar L, von Brandenstein M, Töx U, Nischt R, Coutelle O, Dienes HP,
Odenthal M: Hepatocyte growth factor (HGF) inhibits collagen I and IV
synthesis in hepatic stellate cells by miRNA-29 induction. PLoS One 2011,
6:e24568.
58. Kuo TY, Hsi E, Yang IP, Tsai PC, Wang JY, Juo SH: Computational analysis of
mRNA expression profiles identifies microRNA-29a/c as predictor of
colorectal cancer early recurrence. PLoS One 2012, 7:e31587.
59. Wang CM, Wang Y, Fan CG, Xu FF, Sun WS, Liu YG, Jia JH: miR-29c targets
TNFAIP3, inhibits cell proliferation and induces apoptosis in hepatitis B
virus-related hepatocellular carcinoma. Biochem Biophys Res Commun
2011, 411:586–592.
60. Bauer VL, Braselmann H, Henke M, Mattern D, Walch A, Unger K, Baudis M,
Lassmann S, Huber R, Wienberg J, Werner M, Zitzelsberger HF:
Chromosomal changes characterize head and neck cancer with poor
prognosis. J Mol Med 2008, 86:1353–1365.
61. Wang FE, Zhang C, Maminishkis A, Dong L, Zhi C, Li R, Zhao J, Majerciak V,
Gaur AB, Chen S, Miller SS: MicroRNA-204/211 alters epithelial physiology.
FASEB J 2010, 24:1552–1571.
Sedani et al. Human Genomics 2012, 6:23 Page 9 of 9
http://www.humgenomics.com/content/6/1/2362. Kluwe L, Siebert R, Gesk S, Friedrich RE, Tinschert S, Kehrer-Sawatzki H,
Mautner VF: Screening 500 unselected neurofibromatosis 1 patients for
deletions of the NF1 gene. Hum Mutat 2004, 23:111–116.
63. Dorschner MO, Sybert VP, Weaver M, Pletcher BA, Stephens K: NF1
microdeletion breakpoints are clustered at flanking repetitive sequences.
Hum Mol Genet 2000, 9:35–46.
64. De Raedt T, Brems H, Lopez-Correa C, Vermeesch JR, Marynen P, Legius E:
Genomic organization and evolution of the NF1 microdeletion region.
Genomics 2004, 84:346–360.
65. Upadhyaya M, Ruggieri M, Maynard J, Osborn M, Hartog C, Mudd S,
Penttinen M, Cordeiro I, Ponder M, Ponder BAJ, Krawczak M, Cooper DN:
Gross deletions of the neurofibromatosis type 1 (NF1) gene are
predominantly of maternal origin and commonly associated with a
learning disability, dysmorphic features and developmental delay. Hum
Genet 1998, 102:591–597.
66. Jenne DE, Tinschert S, Dorschner MO, Hameister H, Stephens K, Kehrer-
Sawatzki H: Complete physical map and gene content of the human NF1
tumour suppressor region in human and mouse. Genes Chrom Cancer
2003, 37:111–120.
67. Pasmant E, Masliah-Planchon J, Lévy P, Laurendeau I, Ortonne N, Parfait B,
Valeyrie-Allanore L, Leroy K, Wolkenstein P, Vidaud M, Vidaud D, Bièche I:
Identification of genes potentially involved in the increased risk of
malignancy in NF1-microdeleted patients. Mol Med 2011, 17:79–87.
68. Kozaki K, Imoto I, Mogi S, Omura K, Inazawa J: Exploration of tumour-
suppressive microRNAs silenced by DNA hypermethylation in oral
cancer. Cancer Res 2008, 68:2094–2105.
69. Nie J, Liu L, Zheng W, Chen L, Wu X, Xu Y, Du X, Han W: microRNA-365,
down-regulated in colon cancer, inhibits cell cycle progression and
promotes apoptosis of colon cancer cells by probably targeting cyclin
D1 and Bcl-2. Carcinogenesis 2012, 33:220–225.
70. Tömböl Z, Eder K, Kovács A, Szabó PM, Kulka J, Likó I, Zalatnai A, Rácz G,
Tóth M, Patócs A, Falus A, Rácz K, Igaz P: MicroRNA expression profiling in
benign (sporadic and hereditary) and recurring adrenal
pheochromocytomas. Mod Pathol 2010, 23:1583–1595.
71. Kunej T, Godnic I, Ferdin J, Horvat S, Dovc P, Calin GA: Epigenetic
regulation of microRNAs in cancer: an integrated review of literature.
Mutat Res 2011, 717:77–84.
72. Su Z, Xia J, Zhao Z: Functional complementation between transcriptional
methylation regulation and post-transcriptional microRNA regulation in
the human genome. BMC Genomics 2011, 5:S15.
73. Nana-Sinkam SP, Croce CM: MicroRNAs as therapeutic targets in cancer.
Transl Res 2011, 157:216–225.
74. Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M, Stoffel M:
Silencing of microRNAs in vivo with ‘antagomirs’. Nature 2005, 438:685–689.
75. Ji J, Shi J, Budhu A, Yu Z, Forgues M, Roessler S, Ambs S, Chen Y, Meltzer PS,
Croce CM, Qin LX, Man K, Lo CM, Lee J, Ng IO, Fan J, Tang ZY, Sun HC,
Wang XW: MicroRNA expression, survival, and response to interferon in
liver cancer. N Engl J Med 2009, 361:1437–1447.
76. Meng F, Henson R, Lang M, Wehbe H, Maheshwari S, Mendell JT, Jiang J,
Schmittgen TD, Patel T: Involvement of human micro-RNA in growth and
response to chemotherapy in human cholangiocarcinoma cell lines.
Gastroenterology 2006, 2006(130):2113–2129.
77. Miller TE, Ghoshal K, Ramaswamy B, Roy S, Datta J, Shapiro CL, Jacob S,
Majumder S: MicroRNA-221/222 confers tamoxifen resistance in breast
cancer by targeting p27Kip1. J Biol Chem 2008, 283:29897–29903.
78. Zhao JJ, Lin J, Yang H, Kong W, He L, Ma X, Coppola D, Cheng JQ: MicroRNA-
221/222 negatively regulates estrogen receptor alpha and is associated with
tamoxifen resistance in breast cancer. J Biol Chem 2008, 283:31079–31086.
79. Izzotti A: Molecular medicine and the development of cancer
chemopreventive agents. Ann N Y Acad Sci 2012, 1259:26–32.
80. Han Y, Liu Y, Gui Y, Cai Z: Inducing cell proliferation inhibition and apoptosis
via silencing Dicer, Drosha, and Exportin 5 in urothelial carcinoma of the
bladder. J Surg Oncol 2012, doi:10.1002/jso.23214. Epub ahead of print.
81. Steer CJ, Subramanian S: Circulating microRNAs as biomarkers: a new
frontier in diagnostics. Liver Transpl 2012, 18:265–269.
82. Ajit SK: Circulating microRNAs as biomarkers, therapeutic targets, and
signaling molecules. Sensors (Basel) 2012, 12:3359–3369.
doi:10.1186/1479-7364-6-23
Cite this article as: Sedani et al.: An emerging role for microRNAs in NF1
tumorigenesis. Human Genomics 2012 6:23.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
